150 State St., Albany,
NY, USA, 12207
The uvea is known as the middle layer of the eye. It lies under the white part of the eye which is known as sclera. Moreover, it is made up of the ciliary body, iris and choroid. The uvea structures controls various eye functions such as adjustment to various levels of distances or light of objects. Inflammation of individual or more of these structure is known as uveitis. Uveal melanoma is an uncommon disease but also the most common primary ocular malignancy. Recent technological advancement have improved treatment options and also helps in supporting more accurate prognoses, the risk for mortality and metastasis remains unchanged. Moreover, uveal melanoma is a disease were cancer cells are recognized in the part of the eye called the uvea. The uvea consists cell named melanocytes. When these cell activate and becomes cancerous the cancer is called as melanoma. The uvea includes the iris which is the colored area of the eye and also includes the choroid which is a layer in the back of the eye.
Treatment for uveal melanoma treatment consists of preserving therapies such as laser therapy, radiation, surgical resection and others. Laser therapy primary focuses on thermal energy to destroy tumor cells. This technique is used for small choroidal lesions with a small risk of extrascleral extension. Moreover, laser therapy involves the injection of a light-sensitive compound like verteporfin which is followed by exposure to light in order to generate damaging free oxygen radicals. Furthermore, few of the latest biomarkers adopted the progression and diagnosis of uveal melanoma includes histological, genetic, physiological and radiographic diagnoses which are further projected to drive the growth of uveal melanoma treatment market.
Increase in technological advancement along with continuous improvement in the field of biotechnology have enhanced the identification of possible biomarkers of uveal melanoma. Moreover, raising awareness and increase in use of unique biomarkers which consists of blood biomarkers in the diagnosis and treatment of uveal melanoma which improves the identification accuracy and time invest on the process which is turns further boost the growth of the market. However, lack of awareness about initial stages of disease like eye cancer is restricting the growth of the market. Moreover, to recognize the initial stages of disease for patient is very essential as delay in that can cause loss of death. Furthermore, cost of treatment for eye cancer is pulling down the development of the industry across the globe. Owing its high treatment cost it is not affordable by patients in underdeveloped and underprivileged areas of the world. For example, a large percentage of patients in the UK are experiencing delays or misdiagnosed ultimately causing cancer. Delays may arise owing to slow referral times, failed detection of cancer, delays in administrative or imaging delays. Hence, high cost of treatment along with lack of awareness about the disease is hampering the growth of uveal melanoma treatment market.
Moreover, advancement in therapeutic have improved patient survival in cutaneous melanoma which has further augmented the growth of the market. In number of cases the uveal melanoma patients are diagnosed by an ophthalmologist or optometrist with consequent referral to a specialist ocular oncologist. Moreover, raising innovation and development in treatment of disease like uveal melanoma are projected to boost the global uveal melanoma treatment market. Raising advancement in the treatment have observed like observing the molecule characteristics of uveal melanoma tumor through genetic mutation and alteration studies in novel and patient therapies which is based on mechanism of increasing growth factors receptors like c-kit and c-met to bring good treatment for patients. Moreover, growing research and development activities which are associated with uveal melanoma coupled with raising burden of intraocular melanoma and raising number of clinical trials for new treatment are projected to the drive the global uveal melanoma treatment market.
UVEAL MELANOMA TREATMENT SEGMENTATION:
By Therapy Type
By Location Type
By End User:
North America region contains the largest share and is expected to retain is dominance during the forecast period. The primary reason is the wide availability of advanced healthcare services and facilities which promotes initial detection of uveal melanoma and other various palliative therapies. Moreover, the growth of the uveal melanoma treatment is projected to grow at a great speed owing to increase in awareness regarding clinical trials to get early treatment. Moreover, raising innovation and development in treatment of disease like uveal melanoma are projected to boost the global uveal melanoma treatment market.
FEW KEY PLAYERS IN UVEAL MELANOMA TREATMENT MARKET:
The report offers a comprehensive insight on the Uveal Melanoma Treatment Market share, competitor landscape, market trends, growth, revenue, and key driver’s analysis with coverage of key players, top geographies, product types and end user.
Exhaustive secondary research and in-depth primary interviews with industry experts has been conducted to present qualitative and quantitative insights in the report.
We offer customizations as per client’s specific needs.